GlassScriptPhysician profile
Henry Zaleski
NPI 1043275118
$14,438.42
in general payments reported to CMS, 2019-2025
33 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,520 · 2020: $1,899 · 2021: $2,775 · 2022: $694 · 2023: $492 · 2024: $689 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,550.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| West Therapeutics Development, LLC | $7,104.86 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $4,125.25 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $866.31 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Daiichi Sankyo INC. | $320.56 | 2020-2025 | Enhertu |
| Alexion Pharmaceuticals, INC. | $309.75 | 2021-2025 | Ultomiris |
| Sobi, INC | $273.86 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $232.07 | 2019-2025 | Keytruda |
| Lilly USA, LLC | $185.10 | 2021-2023 | Verzenio |
| Gilead Sciences, INC. | $145.10 | 2021-2024 | Trodelvy |
| Pharmaessentia USA Corporation | $102.61 | 2022-2023 | Besremi |
| Mirati Therapeutics, INC. | $86.38 | 2023-2024 | Krazati |
| E.R. Squibb & Sons, L.L.C. | $67.17 | 2020-2021 | |
| Urogen Pharma, INC. | $64.63 | 2021-2024 | |
| Genzyme Corporation | $62.65 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.50 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $52.02 | 2021 | |
| Aveo Pharmaceuticals, INC. | $45.79 | 2023-2024 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $33.72 | 2021-2023 | Tazverik |
| Tempus Ai, INC | $29.67 | 2025 | Xt Cdx |
| Agios Pharmaceuticals, INC. | $26.05 | 2025 | Pyrukynd |
| Morphosys, US INC. | $24.68 | 2021 | |
| G1 Therapeutics, INC. | $24.60 | 2021 | |
| Stemline Therapeutics INC. | $24.33 | 2023 | Orserdu |
| Lexicon Pharmaceuticals, INC. | $22.36 | 2019 | |
| Astellas Pharma US INC | $20.95 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.92 | 2022 | |
| Kyowa Kirin, INC. | $20.60 | 2024 | Poteligeo |
| Novo Nordisk INC | $20.43 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $19.66 | 2022 | |
| Exelixis INC. | $19.29 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.67 | 2023 | Xarelto |
| Emd Serono, INC. | $11.78 | 2020 | |
| Travere Therapeutics, INC. | $1.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Zaleski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.